| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | MZE782 Chronic Kidney Disease (CKD) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 data readout example | MZE782 Chronic Kidney Disease (CKD) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 data readout example | MZE782 Chronic Kidney Disease (CKD) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Maze Therapeutics, Inc.$31.26
+1.45 (+4.86%)
D 39Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.43 B
EPS
-2.54
P/E Ratio
-
Value Trade
10.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
20.00 M
R&D Expenses
34.15 M
Operating CF
-39.11 M
Total Assets
419.71 M
Total Liabilities
78.01 M
Equity
341.70 M
D/E Ratio
12,345
-0.66 %
Week
-5.67 %
1 Month
-42.34 %
3 Month
-26.34 %
6 Month
59.93 %
5 Year
59.93 %
All Time
Cash Data
Cash Position
352.38 M
Monthly Burn
13.04 M
Runway
25.3 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
575.73 K
52 Week Range
9.73 - 53.65
% held by Insiders
37.71 %
% held by Institutions
57.7 %
Enterprise Value
1.14 B
Total Shares
48.09 M
Short %
14.4 %
Float Shares
28.18 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Maze Therapeutics, Inc.
66Total events
5Upcoming
8Tier-1 (high impact)
2024 – 2027Coverage
Upcoming catalysts 5
Event history 61
Q3 2026
◆Trial InitiationMZE782Trial
Initiation of Phase 2 proof-of-concept trial of MZE782 in CKD
chronic kidney disease (CKD)source ↗
Jun 10, 2026
◆Oral PresentationPresentation
Maze Therapeutics presentation at Goldman Sachs 47th Annual Global Healthcare Conference 2026
Jun 3, 2026
◆Oral PresentationPresentation
Maze Therapeutics presentation at 2026 Jefferies Global Healthcare Conference
Jun 2026
◆Trial InitiationMZE782Trial
Phase 2 proof-of-concept trial of MZE782 in PKU to initiate
Phenylketonuria (PKU)source ↗
Apr 22, 2026
▼Equity OfferingCorporate
Pricing of $150 million registered offering of common stock and pre-funded warrants
Apr 2026
▲Milestone PaymentMZE001Corporate
$20 million milestone payment received from Shionogi for MZE001
Pompe diseasesource ↗
Q2 2026
◆Trial InitiationMZE782Trial
Initiation of Phase 2 proof-of-concept trial of MZE782 in PKU
phenylketonuria (PKU)source ↗
Q1 2026
▲Topline ReadoutMZE829Clinical Data
Positive topline data from Phase 2 HORIZON trial of MZE829 in broad AMKD
APOL1-Mediated Kidney Disease (AMKD)source ↗
Mar 25, 2026
▲Topline ReadoutMZE829Clinical Data
Positive topline data from Phase 2 HORIZON trial of MZE829
APOL1-mediated kidney diseasesource ↗
Mar 25, 2026
●Oral PresentationMZE829Presentation
Investor conference call and webcast to discuss HORIZON data
APOL1-mediated kidney diseasesource ↗
Drug Pipeline Intelligence
D39
Pipeline Score $184M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 55%
Micro Cap (rank 409 of 906)
Percentile RankMaze Therapeutics, Inc. faces pipeline headwinds (39/100), with $459M risk-adjusted pipeline value, led by MZE829 in Proteinuric Kidney Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MZE829 Small molecule | Proteinuric Kidney Disease | Phase 2 | NCT06830629 | 16% | $442M | RECRUITING | 56 | AVERAGE | D (24) | Sep 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MZE829 | broad AMKD | Phase 2 | 2026-05-13 | Positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad APOL1-mediated kidney disease (AMKD) demonstrated proof-of-concept, supporting its advancement into a pivotal trial, with additional data expected in late 2026 or early 2027. Read More | Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Read More | |
MZE829 | broad AMKD | Phase 2 | 2026-05-13 | Positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad APOL1-mediated kidney disease (AMKD) demonstrated proof-of-concept, supporting its advancement into a pivotal trial, with additional data expected in late 2026 or early 2027. Read More | Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Read More | |
MZE829 | broad AMKD | Phase 2 | 2026-05-13 | Positive topline data from the Phase 2 HORIZON trial of MZE829 in patients with broad APOL1-mediated kidney disease (AMKD) demonstrated proof-of-concept, supporting its advancement into a pivotal trial, with additional data expected in late 2026 or early 2027. Read More | Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MAZE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MAZE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MAZEMaze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Jason Coloma will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs Global Healthcare Conference on June 10, 2026. The company is known for developing precision medicines for kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial of MZE829, supporting its advancement into pivotal trials. The company is also on track to initiate Phase 2 trials for MZE782 targeting PKU and CKD. With a strong cash position of $528 million, Maze aims to continue its clinical execution through 2029.
Read more →MAZEMaze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics announced a $150 million registered offering of its common stock at $23.50 per share. The offering includes pre-funded warrants and is expected to close on April 23, 2026. The funds will primarily be used for the development of MZE829 and MZE782, targeting kidney and metabolic diseases. The offering has attracted both new and existing investors.
Read more →MAZEMAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Maze Therapeutics, Inc. due to losses reported after a significant stock price decline. Following the announcement of topline results from its Phase 2 HORIZON trial for MZE829, which showed a mean reduction in uACR, Maze's stock dropped about 33%. The investigation will determine if Maze's executive officers complied with federal securities laws regarding this disclosure. Investors who have suffered losses are encouraged to reach out for more information on potentially recovering their investments.
Read more →MAZEMaze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Maze Therapeutics announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a significant mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease. At week 12, MZE829 led to a 35.6% reduction in uACR, with half of the patients achieving greater than 30% reduction. The treatment was well-tolerated, and the company plans to advance MZE829 into a pivotal program.
Read more →MAZEMaze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q4 and full year 2025, highlighting positive topline data from the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026. Additionally, Neil Kumar has joined the Board of Directors, enhancing the company's leadership.
Read more →MAZEMaze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Maze Therapeutics, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Jason Coloma, Ph.D., will lead the presentation, which will also be available via live webcast. The company focuses on developing precision medicines for kidney and metabolic diseases.
Read more →MAZEMaze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Maze Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, showcasing its advancements in precision medicines for kidney and metabolic diseases. CEO Jason Coloma will speak on February 11, 2026. The company is known for its innovative approach using human genetics to develop treatments, with key products in Phase 2 development.
Read more →MAZEMaze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jason Coloma, Ph.D., will discuss the company's advancements in small molecule precision medicines for kidney and metabolic diseases. The event will be available via live webcast and archived for 30 days.
Read more →MAZEMaze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q3 2025, highlighting positive first-in-human data from its Phase 1 trial of MZE782. The company plans to initiate two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria and chronic kidney disease. Additionally, the ongoing Phase 2 HORIZON trial of MZE829 is expected to provide topline data by the end of Q1 2026.
Read more →MAZEMaze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Maze Therapeutics announced seven presentations at ASN Kidney Week, showcasing advancements in their MZE782 and MZE829 programs. MZE782, a novel SLC6A19 inhibitor, is in Phase 1 trials for PKU and CKD, while MZE829 is in Phase 2 for APOL1-mediated kidney disease. The company emphasizes the importance of genetic insights in developing effective therapies.
Read more →MAZEMaze Therapeutics to Participate in Four Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in four upcoming investor conferences. The company is known for developing small molecule precision medicines targeting kidney and metabolic diseases. Its leading candidates include MZE829 for kidney disease and MZE782 for phenylketonuria and chronic kidney disease. Live webcasts of these events will be available on their website.
Read more →MAZEMaze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Maze Therapeutics has appointed Hervé Hoppenot as the new Chairman of the Board, succeeding Charles Homcy, M.D. Hoppenot, who has extensive experience in the biopharmaceutical industry, expressed his commitment to advancing the company's clinical programs, particularly MZE782 and MZE829. The company is well-positioned for growth with recent funding and promising clinical data.
Read more →MAZEMaze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
Maze Therapeutics has announced a successful oversubscribed private placement, raising approximately $150 million. The funds will be used to further develop its lead candidates, MZE829 and MZE782, targeting kidney and metabolic diseases. The placement involves participation from both new and existing investors and is set to close on September 12, 2025.
Read more →MAZEMaze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Maze Therapeutics announced positive Phase 1 trial results for MZE782, an oral SLC6A19 inhibitor. The trial demonstrated significant increases in urinary phenylalanine excretion and a favorable safety profile, supporting its advancement to Phase 2 trials for treating phenylketonuria (PKU) and chronic kidney disease (CKD) expected to start in 2026.
Read more →MAZEMaze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
Maze Therapeutics has appointed Misbah Tahir as Chief Financial Officer, effective immediately. His extensive experience in the biopharmaceutical sector is expected to support Maze's growth strategy, particularly as the company approaches significant clinical milestones. The company is focused on developing precision medicines for kidney and metabolic diseases, with promising data expected soon.
Read more →MAZEMaze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CK
Maze Therapeutics has reported its second-quarter financial results for 2025, showcasing progress in its clinical trials. The company is expecting to release important proof of mechanism data for its MZE782 compound by Q3 2025, which targets conditions such as phenylketonuria and chronic kidney disease. Additionally, the Phase 2 HORIZON trial of MZE829 is actively enrolling patients, with initial results anticipated by early 2026. Despite its strong cash position, Maze reported no license revenue this quarter and incurred a net loss of $33.7 million.
Read more →MAZEMaze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
Maze Therapeutics will present an overview at the Jefferies 2025 Global Healthcare Conference on June 5, 2025. CEO Jason Coloma, Ph.D., will lead the presentation, which will be available via a live webcast. The company focuses on developing precision medicines for renal, metabolic, and cardiovascular diseases.
Read more →MAZEMaze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1
Maze Therapeutics reported its financial results for the first quarter of 2025, indicating a solid cash position of $294.4 million to fund ongoing clinical trials. The company emphasized progress in its MZE829 Phase 2 trial for APOL1 Kidney Disease, with initial data expected in Q1 2026, while MZE782 is currently in Phase 1 trials with results anticipated in Q3 2025. The net loss for this quarter was $32.8 million, reflecting an increase in R&D spending as therapies advance. Despite the losses, the company expresses optimism about its pipeline and the potential market impact.
Read more →MAZEMaze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Maze Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025. CEO Jason Coloma, Ph.D., will present an overview of the company and engage in one-on-one meetings. The presentation will be accessible on the company's website, with an archived replay available for 60 days. This participation reflects Maze's commitment to transparency and investor relations as they advance their precision medicine initiatives.
Read more →MAZEMaze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782
Maze Therapeutics reported its fourth quarter and full-year financial results for 2024, revealing a net income of $52.2 million thanks to license revenue from a partnership with Shionogi. The company is advancing its MZE829 and MZE782 candidates through multiple clinical trials, with significant milestones expected in the coming years, including initial data from the MZE829 Phase 2 trial in early 2026. The company also strengthened its financial position through a $140 million IPO, providing a cash runway into the second half of 2027. Continued financial losses highlight challenges ahead as Maze pushes forward with its developmental pipeline.
Read more →MAZEMaze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics has begun dosing patients in its Phase 2 HORIZON clinical trial for MZE829, an oral APOL1 inhibitor aimed at treating APOL1 kidney disease (AKD). The trial includes a diverse group of patients, reflecting various severity levels of the disease, with a primary endpoint focusing on reducing proteinuria. The company's approach seeks to establish proof of concept for MZE829, which may serve as a significant advancement in managing AKD, affecting over one million patients in the U.S. There is anticipation for interim data readout by early 2026.
Read more →MAZEMaze Therapeutics Announces Pricing of Upsized Initial Public Offering
Maze Therapeutics has announced the pricing of its upsized initial public offering, offering 8,750,000 shares at $16.00 each, projected to yield gross proceeds of $140 million. The company plans to begin trading on the Nasdaq under the ticker 'MAZE' on January 31, 2025. The offering includes a 30-day option for underwriters to purchase additional shares. The close of the offering is expected on February 3, 2025, pending customary closing conditions. Maze focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases.
Read more →Competitive Position
How MAZE ranks across every disease it competes inCompetitive Position is a premium feature
See how MAZE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial